Publication: A new bronchodilator response grading strategy ıdentifies distinct patient populations
dc.contributor.author | Hansen, James E. | |
dc.contributor.author | Porszasz, Janos | |
dc.contributor.author | Stringer, William W. | |
dc.contributor.author | Pak, Youngju | |
dc.contributor.author | Rossiter, Harry B. | |
dc.contributor.author | Casaburi, Richard | |
dc.contributor.buuauthor | Dilektaşlı, Aslı G. | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Dahili Tıp Bilimleri | |
dc.contributor.department | Göğüs Hastalıkları Bölümü | |
dc.contributor.orcid | 0000-0001-7099-9647 | tr_TR |
dc.contributor.scopusid | 36466376600 | tr_TR |
dc.date.accessioned | 2023-06-15T13:34:42Z | |
dc.date.available | 2023-06-15T13:34:42Z | |
dc.date.issued | 2019-12 | |
dc.description.abstract | Rationale: A positive bronchodilator response (BDR) according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines require both 200 ml and 12% increase in forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) after bronchodilator inhalation. This dual criterion is insensitive in those with high or low FEV1. Objectives: To establish BDR criteria with volume or percentage FEV1 change. Methods: The largest FEV1 and FVC were identified fromthree pre- and three post-bronchodilator maneuvers in COPDGene (Genetic Epidemiology of COPD) participants. A total of 7,741 individuals with coefficient of variation less than 15% for both FEV1 and FVC formed bronchodilator categories of FEV1 response: negative (<= 0.00% or <= 0.00 L), minimal (>0.00% to <= 9.00% or >0.00 L to <= 0.09 L), mild (>9.00% to <= 16.00% or.0.09 L to <0.16 L), moderate (>16.00% to <= 26.00% or >0.16 L to <= 0.26 L), and marked (>26.00% or >0.26 L). These response size categories are based on empirical limits considering average FEV1 increase of approximately 160 ml and the clinically important difference for FEV1. To compare flow and volume response characteristics, BDR-FEV1 category assignments were applied for the BDR-FVC response. Results: Twenty percent met mild and 31% met moderate or marked BDR-FEV1 criteria, whereas 12% met mild and 33% met moderate or marked BDR-FVC criteria. In contrast, only 20.6% met ATS/ERS positive criteria. Compared with the negative BDR-FEV1 category, the minimal, mild, moderate, and marked BDR-FEV1 categories were associated with greater 6-minute-walk distance and lower St. George's Respiratory Questionnaire and modified Medical Research Council dyspnea scale scores. Compared with negative BDR, moderate and marked BDR-FEV1 categories were associated with fewer exacerbations, and minimal BDR was associated with lower computed tomography airway wall thickness. Compared with the negative category, all BDR-FVC categories were associated with increasing emphysema percentage and gas trapping percentage. Moderate and marked BDR-FVC categories were associated with higher St. George's Respiratory Questionnaire scores but fewer exacerbations and lower dyspnea scores. Conclusions: BDR grading by FEV1 volume or percentage response identified subjects otherwise missed by ATS/ERS criteria. BDR grades were associated with functional exercise performance, quality of life, exacerbation frequency, dyspnea, and radiological airway measures. BDR grades in FEV1 and FVC indicate different clinical and radiological characteristics. | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) | en_US |
dc.description.sponsorship | National Center for Advancing Translational Sciences through UCLA CTSI Grant | en_US |
dc.identifier.citation | Hansen, J. E. vd. (2019). ''A new bronchodilator response grading strategy ıdentifies distinct patient populations''. Annals of the American Thoracic Society, 16(12), 1504-1517. | en_US |
dc.identifier.endpage | 1517 | tr_TR |
dc.identifier.issn | 1546-3222 | |
dc.identifier.issn | 2325-6621 | |
dc.identifier.issue | 12 | tr_TR |
dc.identifier.pubmed | 31404502 | tr_TR |
dc.identifier.scopus | 2-s2.0-85075774981 | tr_TR |
dc.identifier.startpage | 1504 | tr_TR |
dc.identifier.uri | https://doi.org/10.1513/AnnalsATS.201901-030OC | |
dc.identifier.uri | https://www.atsjournals.org/doi/10.1513/AnnalsATS.201901-030OC | |
dc.identifier.uri | http://hdl.handle.net/11452/33051 | |
dc.identifier.volume | 16 | tr_TR |
dc.identifier.wos | 000499727700010 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Amer Thoracic | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Annals of the American Thoracic Society | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Airflow obstruction | en_US |
dc.subject | Respiratory System | en_US |
dc.subject | Bronchodilator responsiveness | en_US |
dc.subject | Forced expiratory volume in 1 second | en_US |
dc.subject | Computed-tomography | en_US |
dc.subject | Airway-obstruction | en_US |
dc.subject | Overlap syndrome | en_US |
dc.subject | Reversibility | en_US |
dc.subject | Responsiveness | en_US |
dc.subject | Copd | en_US |
dc.subject | Fvc | en_US |
dc.subject | Fev1 | en_US |
dc.subject | Variability | en_US |
dc.subject | Diagnosis | en_US |
dc.subject.emtree | Beta 2 adrenergic receptor stimulating agent | en_US |
dc.subject.emtree | Salbutamol | en_US |
dc.subject.emtree | Bronchodilating agent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Airway obstruction | en_US |
dc.subject.emtree | Airway remodeling | en_US |
dc.subject.emtree | American Thoracic Society European Respiratory Society criteria | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bronchodilator response grading strategy | en_US |
dc.subject.emtree | Chronic obstructive lung disease | en_US |
dc.subject.emtree | Cohort analysis | en_US |
dc.subject.emtree | Comparative study | en_US |
dc.subject.emtree | Computer assisted tomography | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Current smoker | en_US |
dc.subject.emtree | Disease exacerbation | en_US |
dc.subject.emtree | Dyspnea | en_US |
dc.subject.emtree | Ex-smoker | en_US |
dc.subject.emtree | Exercise | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Forced expiratory volume | en_US |
dc.subject.emtree | Forced vital capacity | en_US |
dc.subject.emtree | Functional status | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Lung emphysema | en_US |
dc.subject.emtree | Lung volume | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Modified medical research council dyspnea scale | en_US |
dc.subject.emtree | Morbidity | en_US |
dc.subject.emtree | Practice guideline | en_US |
dc.subject.emtree | Quality of life | en_US |
dc.subject.emtree | Respiratory tract disease assessment | en_US |
dc.subject.emtree | Six minute walk test | en_US |
dc.subject.emtree | St. George respiratory questionnaire | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Chronic obstructive lung disease | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Forced expiratory volume | en_US |
dc.subject.emtree | Lung function test | en_US |
dc.subject.emtree | Multicenter study | en_US |
dc.subject.emtree | Pathophysiology | en_US |
dc.subject.emtree | Questionnaire | en_US |
dc.subject.emtree | Severity of illness index | en_US |
dc.subject.emtree | Spirometry | en_US |
dc.subject.emtree | Statistical model | en_US |
dc.subject.emtree | Vital capacity | en_US |
dc.subject.emtree | X-ray computed tomography | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Bronchodilator agents | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Forced expiratory volume | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Linear models | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Pulmonary disease, chronic obstructive | en_US |
dc.subject.mesh | Quality of life | en_US |
dc.subject.mesh | Respiratory function tests | en_US |
dc.subject.mesh | Severity of illness index | en_US |
dc.subject.mesh | Spirometry | en_US |
dc.subject.mesh | Surveys and questionnaires | en_US |
dc.subject.mesh | Tomography, X-Ray computed | en_US |
dc.subject.mesh | Vital capacity | en_US |
dc.subject.scopus | Undifferentiated Connective Tissue Diseases; Adrenal Cortex Hormone; Global Initiatives | en_US |
dc.subject.wos | Respiratory system | en_US |
dc.title | A new bronchodilator response grading strategy ıdentifies distinct patient populations | en_US |
dc.type | Article | |
dc.wos.quartile | Q1 | en_US |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Dahili Tıp Bilimleri/Göğüs Hastalıkları Bölümü | tr_TR |